Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Janice, Mehnert"'
Autor:
Ticiana A. Leal, Marina N. Sharifi, Nancy Chan, Robert Wesolowski, Anita A. Turk, Justine Y. Bruce, Ruth M. O'Regan, Jens Eickhoff, Lisa M. Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B. Wisinski
Publikováno v:
Cancer Medicine, Vol 11, Iss 21, Pp 3969-3981 (2022)
Abstract Background Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and pacl
Externí odkaz:
https://doaj.org/article/d110893465fc4eceb9dd0c7b44d3c53f
Autor:
Min Yi, Celeste Lebbe, Parminder Singh, Omid Hamid, Jason Chesney, Igor Puzanov, Mohammed Milhem, Merrick Ross, Janice Mehnert, Theodore Logan, Philip Friedlander, Frances Collichio, Claus Garbe, John Glaspy, Axel Hauschild, Wendy Snyder
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/8335d9359bfa40079fa735a2c737d38f
Autor:
Andrew Haydon, Rebecca Johnson, Iman Osman, Janice Mehnert, Suthee Rapisuwon, Douglas Johnson, Ryan Sullivan, Matteo Carlino, Alexander Menzies, Prachi Bhave, James Patrinely, Aleigha Lawless, Amelia Sawyers, Maya Dimitrova, Hui Yeohc, Marisa Palmeri, Elizabeth Davis, Georgina Long
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/b2afcd48507b46a58a5169e0c18c2d0a
Autor:
Assaf, Berger, Kenneth, Bernstein, Juan Diego, Alzate, Reed, Mullen, Joshua S, Silverman, Erik P, Sulman, Bernadine R, Donahue, Anna C, Pavlick, Jason, Gurewitz, Monica, Mureb, Janice, Mehnert, Kathleen, Madden, Amy, Palermo, Jeffrey S, Weber, John G, Golfinos, Douglas, Kondziolka
Publikováno v:
Journal of Neuro-Oncology. 158:471-480
New therapies for melanoma have been associated with increasing survival expectations, as opposed to the dismal outcomes of only a decade ago. Using a prospective registry, we aimed to define current survival goals for melanoma patients with brain me
Autor:
Daniel Y Wang, Meghan J Mooradian, DaeWon Kim, Neil J Shah, Sarah E Fenton, Robert M Conry, Rutika Mehta, Ann W. Silk, Alice Zhou, Margaret L Compton, Rami N Al-Rohil, Sunyoung Lee, Amber L Voorhees, Lisa Ha, Svetlana McKee, Jacqueline T Norrell, Janice Mehnert, Igor Puzanov, Jeffrey A Sosman, Sunandana Chandra, Geoffrey T Gibney, Suthee Rapisuwon, Zeynep Eroglu, Ryan Sullivan, Douglas B Johnson
Publikováno v:
OncoImmunology, Vol 8, Iss 1 (2019)
Colitis is a frequent, clinically-significant immune-related adverse event caused by anti-programmed death-1 (PD-1). The clinical features, timing, and management of colitis with anti-PD-1-based regimens are not well-characterized. Patients with adva
Externí odkaz:
https://doaj.org/article/47c6c7c86d354dbcaa13aa6907596ec4
Autor:
Ticiana A. Leal, Marina N. Sharifi, Nancy Chan, Robert Wesolowski, Anita A. Turk, Justine Y. Bruce, Ruth M. O'Regan, Jens Eickhoff, Lisa M. Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B. Wisinski
Publikováno v:
Cancer Medicine. 11:3969-3981
Inhibitors of poly(ADP-ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and paclitaxel.We conducted a
Autor:
Assaf Berger, Kenneth Bernstein, Juan AlzateRamirez, Reed Mullen, Joshua S. Silverman, Erik P. Sulman, Bernadine Donahue, Pavlick Anna, Jason Gurewitz, Monica Mureb, Janice Mehnert, Kathleen Madden, Amy Palermo, Jeffrey Weber, John G. Golfinos, Douglas Kondziolka
Publikováno v:
Neurosurgery. 69:48-49
Autor:
Alexander Spira, Valentina Gambardella, Shumei Kato, Cesar Batista Perez, Meredith Mckean, Maria Gonzalez Cao, Richard Kim, Chris T Chen, Antoine Italiano, Philippe Cassier, Janice Mehnert, Bartosz Chmielowski, Gerri Lee, Paul Severson, Caro Unger, Xiaowei Guan, Richard Williams, Georgina Long
Publikováno v:
Cancer Research. 83:CT032-CT032
Background: Patients with cancers driven by BRAF Class II (C II) or C III alterations and/or NRAS mutations are unlikely to benefit from approved BRAF-targeted therapies and have few other treatment options. Exarafenib is a potentially best in class
Autor:
George Jour, Irineu Illa-Bochaca, Milad Ibrahim, Douglas Donnelly, Kelsey Zhu, Eleazar Vega-Saenz de Miera, Varshini Vasudevaraja, Valeria Mezzano, Sitharam Ramswami, Yu-Hsin Yeh, Carolyn Winskill, Rebecca A. Betensky, Janice Mehnert, Iman Osman
Publikováno v:
The Journal of investigative dermatology.
There is currently no targeted therapy to treat NF1-mutant melanomas. In this study, we compared the genomic and transcriptomic signatures of NF1-mutant and NF1 wild-type melanoma to reveal potential treatment targets for this subset of patients. Gen
Autor:
Aaron W, Kangas-Dick, Alissa, Greenbaum, Victor, Gall, Roman, Groisberg, Janice, Mehnert, Chunxia, Chen, Dirk F, Moore, Adam C, Berger, Vadim, Koshenkov
Publikováno v:
Annals of surgical oncology. 28(8)
A significant proportion of deaths from cutaneous melanoma occur among patients with an initial diagnosis of stage 1 or 2 disease. The Decision-Dx Melanoma (DDM) 31-gene assay attempts to stratify these patients by risk of recurrence. This study aime